SDP Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Virtual Annual Meeting I 2021

April 16, 2021

Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently presented new findings on a range of investigational agents from the company’s pipeline at the American Association for Cancer Research (AACR) Virtual Annual Meeting I.

The data presented at the meeting include preclinical and Phase 1 clinical data evaluating the potential anti-cancer activity of the PKM2 activator TP-1454, PIM inhibitor TP-3654, TNK1 inhibitor TP-5809 and CDK9 inhibitor alvocidib. Additionally, Sumitomo Dainippon Pharma Co., Ltd., the parent company of Sumitomo Dainippon Pharma Oncology (SDP Oncology), presented findings from preclinical studies of DSP-0509, a TLR7 agonist.

“As we advance our investigational agents, we are pleased to present the latest research on our diverse pipeline to the scientific community at the AACR Virtual Annual Meeting. These data reflect our relentless commitment to propelling drug discovery in oncology and our progress in advancing research in hematologic and solid malignancies,” said Patricia S. Andrews, Chief Executive Officer and Global Head of Oncology, SDP Oncology.

“Presenting before this distinguished organization is a recognition of the promising research that SDP Oncology is moving forward to improve  cancer treatments,” said Kelvyn Cullimore, president and CEO of BioUtah.